Utility of Reverse-Phase Protein Array for Refining Precision Oncology
Utility of Reverse-Phase Protein Array for Refining Precision Oncology
复制标题
反相蛋白阵列在完善精准肿瘤学中的应用
DOI：
10.1007/978-981-32-9755-5_13
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Yamada T
中科院分区：
文献类型：
--
作者：
Masuda M;Yamada T
尽管靶向治疗在过去20年里取得了早期的成功，下一代测序技术也在不断改进，但基因组学驱动的精确肿瘤学只帮助了一小部分癌症患者；因此，治疗方案仍然无法与绝大多数癌症患者匹配。很明显，基因组图谱本身在靶向治疗的最佳患者选择方面是有限的。基于蛋白质组学的方法(与基于基因组学和基于转录组学的方法不同)捕获了直接促成癌症发病机制的生物学过程(例如，蛋白质表达模式的多样性和翻译后修饰)。这鼓励将一致的蛋白质组分析结合到精确肿瘤学的下一阶段。反相蛋白质阵列(RPPA)因其能够利用有限的临床样本精确地定位信号状态而非常适合于药效学分析。此外，RPPA平台的成本效益和快速周转时间在临床环境中提供了比现有分子图谱技术更大的优势。在这一章中，我们首先回顾基因组学驱动的精确肿瘤学的现状，以及它的局限性和挑战。最后，我们讨论了RPPA技术作为提高精确度肿瘤学的一种手段的实用性。
Despite the early successes of targeted therapies and continuous improvements in next-generation sequencing technology over the last two decades, genomics-driven precision oncology has helped only a minority of cancer patients; thus treatment regimens are still not matched to the vast majority of cancer patients. It has become apparent that genomic profiling in itself is limited with respect to optimal selection of patients for targeted therapy. Proteomics-based approaches (in contrast to genomics-based and transcriptomics-based approaches) capture biological processes (e.g., diversity of protein expression patterns and post-translational modifications) directly contributing to cancer pathogenesis. This encourages incorporation of concordant proteomic analyses into the next stage of precision oncology. Reverse-phase protein array (RPPA) is well suited to pharmacodynamic analysis due to its ability to precisely map signaling status using limited amounts of clinical sample. In addition, the cost-effectiveness and rapid turnaround time of the RPPA platform offer a substantial advantage over existing molecular profiling technologies in a clinical setting. In this chapter, we begin by reviewing the current status of genomics-driven precision oncology, along with its limitations and challenges. Finally, we discuss the utility of RPPA technology as a means of improving precision oncology.